Top

Prithviraj Bose, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Bose

After obtaining his medical degree in 2001 from the University of Calcutta in his hometown of Kolkata, India, where he attended the Calcutta Medical College, Dr. Bose began a residency in general medicine at the Institute of Post-Graduate Medical Education and Research in Kolkata, which he left in early 2004 to move to the United States. He then completed an internship in internal medicine at a University of Washington affiliate in Spokane, Washington in 2005, and residency at the Henry Ford Hospital in Detroit, Michigan in 2007, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma from 2017 through 2010. Dr. Bose became American Board of Internal Medicine-certified in hematology and medical oncology in 2010.

He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, VA, where he was an assistant professor of medicine and a member of the NCI-designated VCU Massey Cancer Center between July 2010 and January 2015. At VCU, Dr. Bose took care of patients with diverse hematologic malignancies and teamed up with noted translational scientist, Steven Grant, to design early phase clinical trials of novel, targeted drug combinations in AML.

In the Department of Leukemia at The University of Texas MD Anderson Cancer Center, which he joined in early 2015, Dr. Bose’s major clinical and research focus is on myeloproliferative neoplasms (MPNs). He works closely with Dr. Srdan Verstovsek, chief of the section of MPNs. The two have authored many articles together in peer-reviewed journals and books and continue to do so. Dr. Bose is also heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis. He has presented his research at international conferences and regularly speaks on MPN topics. Dr. Bose’s other area of interest is chronic lymphocytic leukemia (CLL). His clinical practice consists largely of patients with MPNs or CLL, although he also treats many patients with MDS, CML and acute leukemias.

Dr. Bose sits on the MPN panel of the National Comprehensive Cancer Network. His work has appeared in leading peer-reviewed journals such as The New England Journal of Medicine, Blood, and Cancer Cell, as well as in Williams’ Hematology. Dr. Bose was previously editor-in-chief of Drug Target Insights, and is currently on the editorial board of Hematology. In 2011, Dr. Bose, then a first-year faculty member at Virginia Commonwealth University, was selected to participate in the American Society of Hematology’s prestigious Clinical Research Training Institute. Now a naturalized US citizen, Dr. Bose was granted permanent residence in the United States in 2013 in the select “outstanding researcher” (first preference) category.

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001	Calcutta Medical College, University of Calcutta, Kolkata, IND, MBBS, Medicine

Postgraduate Training

2007-2010	Clinical Fellowship, Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
2005-2007	Clinical Residency, Internal Medicine, Henry Ford Hospital, Detroit, MI
2004-2005	Clinical Internship, Internal Medicine, Internal Medicine Residency Spokane, Spokane, WA
2003-2004	Clinical Residency, General Medicine, Institute of Post Graduate Medical Education and Research, Kolkata

Board Certifications

2010	American Board of Internal Medicine - Hematology
2010	American Board of Internal Medicine - Medical Oncology
2007	American Board of Internal Medicine

Experience & Service

Academic Appointments

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017

Assistant Professor, Department of Internal Medicine, Division of Hematology/Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA, 2010 - 2015

Other Appointments/Responsibilities

Member, MPN and SM panels, National Comprehensive Cancer Network, Plymouth Meeting, PA, 2018 - Present

Member, Protocol Review and Monitoring Committee, VCU Massey Cancer Center, Richmond, VA, 2013 - 2015

ER Physician, Oklahoma City VA Medical Center, Oklahoma City, OK, 2009 - 2010

Institutional Committee Activities

Member, Transfusion and Patient Blood Management Committee, 2021 - Present

Member, Readmissions Review Committee, 2020 - Present

Member, Scientific Review Committee (CRC) # 4, 2016 - Present

Honors & Awards

2011	Physician's Recognition Award with Commendation, American Medical Association
2011	Clinical Research Training Institute, American Society of Hematology

Selected Publications

Peer-Reviewed Articles

Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033-1062, 2022. PMID: 36075392.
Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(4):210-223, 2022. e-Pub 2021. PMID: 34840087.
Bose P, Mesa RA. Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leuk Lymphoma 63(4):1-15, 2022. e-Pub 2021. PMID: 34775887.
Vachhani P, Verstovsek S, Bose P. "Disease Modification" in Myelofibrosis: an elusive goal?. J Clin Oncol 40(11):1147-1154, 2022. e-Pub 2022. PMID: 35084934.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for Myelofibrosis Patients with Anemia. J Hematol Oncol 15(1):7, 2022. e-Pub 2022. PMID: 35045875.
Pasca S, Chifotides HT, Verstovsek S, Bose P. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol 366:83-124, 2022. e-Pub 2021. PMID: 35153007.
Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J 12(1):23, 2022. e-Pub 2022. PMID: 35102145.
Lovell AR, Jammal N, Bose P. Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. Ther Adv Hematol 13:20406207221116577, 2022. e-Pub 2022. PMID: 35966045.
Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang FF, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT. Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nat Commun 13(1):190, 2022. e-Pub 2022. PMID: 34987156.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJ. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med 27(12):2192-2199, 2021. e-Pub 2021. PMID: 34873345.
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 27(12):2183-2191, 2021. e-Pub 2021. PMID: 34873347.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II Study of Azacitidine with Pembrolizumab in Patients with Intermediate-1 or Higher-Risk Myelodysplastic Syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
Bose P, Verstovsek S. SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis. Clin Lymphoma Myeloma Leuk 21(10):641-649, 2021. e-Pub 2021. PMID: 34272171.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA. Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol 34(9):1673-1685, 2021. e-Pub 2021. PMID: 33990705.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Bose P, Verstovsek S. Avapritinib for Systemic Mastocytosis. Expert Rev Hematol 14(8):687-696, 2021. e-Pub 2021. PMID: 34289787.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. PMID: 34424319.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica Online ahead of print(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol, 2021. e-Pub 2021. PMID: 33882481.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of Gli1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet Therapy with Venetoclax, FLT3 Inhibitor and Decitabine for FLT3-mutated Acute Myeloid Leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Bose P, Gandhi V. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Fac Rev 10:22, 2021. e-Pub 2021. PMID: 33718939.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver N, Kadia T, Chifotides H, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Venetoclax Combinations in Patients with Acute Leukemia from Myeloproliferative Neoplasms: Single Center Experience. Blood Adv 5(8):2156-2164, 2021. PMID: 33885751.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, García-Gutiérrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 4(22):5825-5835, 2020. PMID: 33232476.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
Bose P, Masarova L, Verstovsek S. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050168.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(9):1248-1269, 2020. PMID: 32886902.
Bose P, Verstovsek S. Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma 61(8):1797-1809, 2020. e-Pub 2020. PMID: 32297800.
Bose P, Verstovsek S. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Hemasphere 4(4):e424, 2020. e-Pub 2020. PMID: 32903304.
Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs 29(6):525-536, 2020. e-Pub 2020. PMID: 32693648.
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. PMID: 32068780.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2019. PMID: 32035785.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2019. PMID: 31682008.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2019. PMID: 31553487.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol 37(3):240-252, 2019. e-Pub 2019. PMID: 31013548.
Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv 3(15):2264-2271, 2019. PMID: 31350306.
Gordon SW, McGuire WP, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol 42(8):649-654, 2019. PMID: 31305287.
Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 14(4):310-327, 2019. PMID: 31228096.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2018. PMID: 30575820.
Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855-1866, 2019. e-Pub 2019. PMID: 30811597.
Bose P, Verstovsek S. MF Management. Hemasphere 3(suppl 2):149-152, 2019. e-Pub 2019.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2018. PMID: 30328139.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of co-treatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol 10:2040620719870052, 2019. e-Pub 2019. PMID: 31516686.
Bose P. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opin Orphan Drugs 7(10):415-425, 2019. e-Pub 2019. PMID: 33094033.
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(12):1500-1537, 2018. PMID: 30545997.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-3, 2018. e-Pub 2018. PMID: 30242087.
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin Infect Dis 67(10):1610-1613, 2018. e-Pub 2018. PMID: 29771293.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res 72:92-95, 2018. e-Pub 2018. PMID: 30118897.
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18(9):569-575.e1, 2018. e-Pub 2018. PMID: 30122201.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
Bose P, Swaminathan M. JAK inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin 34(5):1-6, 2018. e-Pub 2018. PMID: 29415577.
Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of Ruxolitinib in combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2017. PMID: 29134664.
Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep 6(1):155-611, 2018. e-Pub 2017. PMID: 29375856.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. PMID: 28919634.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31080940.
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 58(9):1-17, 2017. e-Pub 2017. PMID: 28140720.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal Evolution and Outcomes in Myelofibrosis After Ruxolitinib Discontinuation. Blood 130(9):1125-31, 2017. e-Pub 2017. PMID: 28674026.
Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res 58:14-22, 2017. e-Pub 2017. PMID: 28380402.
Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood 130(2):115-125, 2017. e-Pub 2017. PMID: 28500170.
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. A Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma. Leuk Lymphoma 58(6):1349-1357, 2017. e-Pub 2017. PMID: 28103725.
Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is Frequently Low in Patients with Myelofibrosis: Clinical Relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
Abou Zahr A, Bose P, Keating MJ. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother 18(9):857-873, 2017. e-Pub 2017. PMID: 28446054.
Bose P, Abou Zahr A, Verstovsek S. Investigational Janus Kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs 26(6):723-734, 2017. e-Pub 2017. PMID: 28441920.
Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel Hematological Parameters for the Evaluation of Patients with Myeloproliferative Neoplasms: the Immature Platelet and Reticulocyte Fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma 58(4):1-6, 2017. e-Pub 2016. PMID: 27494751.
Falchi L, Bose P, Newberry KJ, Verstovsek S. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. Br J Haematol 176(3):352-364, 2017. e-Pub 2016. PMID: 27984634.
Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res 6:1924, 2017. e-Pub 2017. PMID: 29152232.
Bose P, Verstovsek S. Investigational histone dea¬cetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs 25(12):1393-1403, 2016. e-Pub 2016. PMID: 27756180.
Bose P, Verstovsek S. Myelofibrosis: An Update on Drug Therapy in 2016. Expert Opin Pharmacother 17(18):2375-2389, 2016. e-Pub 2016. PMID: 27774820.
Bose P, Verstovsek S. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw 14(12):1613-1624, 2016. PMID: 27956543.
Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol 12(11):1-12, 2016. e-Pub 2016. PMID: 27686109.
Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia 30(8):1803-4, 2016. PMID: 27198052.
Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 7(27):42625-42638, 2016. e-Pub 2016. PMID: 27213589.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22(5):1067-75, 2016. e-Pub 2015. PMID: 26446942.
Bose P, Verstovsek S. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer 122(5):681-92, 2016. e-Pub 2015. PMID: 26717494.
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas. Leuk Lymphoma 57(3):1-30, 2016. e-Pub 2015. PMID: 26284612.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized Multicenter Phase 2 Study of Timed Sequential Therapy with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed Adult Acute Myeloid Leukemia (AML). Haematologica 100(9):172-179, 2015. e-Pub 2015. PMID: 26022709.
Dinnel J, Moore BL, Skiver BM, Bose P. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. Core Evid 10:23-38, 2015. e-Pub 2015. PMID: 25610345.
Vachhani P, Bose N, Brodeur JP, Holkova B, Bose P. Remission of rheumatoid arthritis on brentuximab vedotin. Rheumatology (Oxford) 53(12):2314-5, 2014. e-Pub 2014. PMID: 25239883.
Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother 15(16):2443-59, 2014. e-Pub 2014. PMID: 25263936.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20(22):5652-62, 2014. e-Pub 2014. PMID: 25248382.
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143(3):323-36, 2014. e-Pub 2014. PMID: 24769080.
Vachhani P, Bose P, Rahmani M, Grant S. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics 46(13):448-56, 2014. e-Pub 2014. PMID: 24824212.
Vachhani P, Bose P. Isolated gastric myeloid sarcoma: a case report and review of the literature. Case Rep Hematol 2014:541807, 2014. e-Pub 2014. PMID: 25105036.
Skiver BM, Patel SB, Bose P. It is not always immune thrombocytopenia: a case of MYH9-related platelet disorder caused by a novel mutation. Eur J Haematol 91(2):191-2, 2013. e-Pub 2013. PMID: 23489225.
Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 22(6):723-38, 2013. e-Pub 2013. PMID: 23647051.
Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep 2(1):12-14, 2013. PMID: 23977453.
Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk Res Rep 2(1):18-20, 2013. PMID: 23977454.
Bose P, Murugan P, Gillies E, Holter JL. Extraosseous Ewing's sarcoma of the pancreas. Int J Clin Oncol 17(4):399-406, 2012. e-Pub 2011. PMID: 21892669.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol 69(6):1657-67, 2012. e-Pub 2012. PMID: 22349810.
Bose P, Parekh HD, Holter JL, Greenfield RA. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. J Clin Microbiol 49(4):1674-5, 2011. e-Pub 2011. PMID: 21270218.
Bose P, Dunn ST, Yang J, Allen R, El-Khoury C, Tfayli A. c-Kit expression and mutations in phyllodes tumors of the breast. Anticancer Res 30(11):4731-6, 2010. PMID: 21115932.
Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 18(11):1735-51, 2009. PMID: 19780706.
Bose P, Hussein KK, Terrell DR, Berger D, Rice L, George JN. Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients. Am J Hematol 84(7):459-61, 2009. PMID: 19484732.
Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol 82(6):490-2, 2009. e-Pub 2009. PMID: 19220417.
Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143-4, 2009. PMID: 19439755.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. e-Pub 2020. PMID: 32697338.
Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, van Etten RA. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. e-Pub 2020. PMID: 32592408.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. e-Pub 2020. PMID: 32499238.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis. e-Pub 2020. PMID: 32236406.
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome. Leuk Lymphoma:1-14. e-Pub 2020. PMID: 33356689.
Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol. e-Pub 2021. PMID: 34350483.
Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. e-Pub 2021. PMID: 33551345.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. e-Pub 2022. PMID: 36054032.
Harrison CN, Hobbs GS, Bose P, Kuykendall AT, Song J, Gerds AT. Treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: current evidence and real-world implications.
Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma:1-5. e-Pub 2022. PMID: 35787095.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. e-Pub 2022. PMID: 35690645.
Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol. e-Pub 2022. PMID: 35368098.

Invited Articles

Bose P. A Young Woman with Thrombocytosis. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S14-S17, 2020. PMID: 32862851.
Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol 111(2):192-199, 2020. e-Pub 2019. PMID: 31630335.
Bose P. Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk 19(suppl 1):S36-S39, 2019.
Bose P, Alfayez M, Verstovsek S. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol 20(1):5, 2019. e-Pub 2019. PMID: 30675650.
Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki 60(9):1176-1185, 2019. PMID: 31597841.
Bose P, Verstovsek S. Accelerated Phase Myelofibrosis. Clin Lymphoma Myeloma Leuk 18(Suppl. 1):S40-S42, 2018.
Bose P, Verstovsek S. Management of myelofibrosis-related cytopenias. Curr Hematol Malig Rep 13(3):164-172, 2018. PMID: 29796726.
Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18(1):1-12, 2018. PMID: 29277359.
Bose P. Myelofibrosis with cytopenias. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S30-S31, 2017.
Bose P, Verstovsek S. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 17S:S43-S52, 2017. PMID: 28760302.
Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol 18(3):17, 2017. e-Pub 2017. PMID: 28286924.
Bose P, Verstovsek S. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk 16 Suppl:S105-13, 2016. PMID: 27521306.
Bose P, Grant S. Rational combinations of targeted agents in AML. J Clin Med 4(4):634-664, 2015. e-Pub 2015. PMID: 26113989.
Bose P, Qubaiah O.. A review of tumor lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics 36(3):299-326, 2011. PMID: 21501203.

Editorials

Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma 60(7):1603-1605, 2019. PMID: 30724681.
Bose P, Konopleva MY. ORY-1001: Overcoming the differentiation block in AML. Cancer Cell 33(3):342-343, 2018. PMID: 29533778.
Bose P, Konopleva MY. T-PLL: another check on the venetoclax list?. Blood 130(23):2447-2448, 2017. PMID: 29217697.
Bose P, Verstovsek S. Ruxolitinib for Essential Thrombocythemia?. Oncoscience 4(11-12):148-149, 2017. PMID: 29344542.
Bose P, Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res 38(8):862-5, 2014. PMID: 24996975.
Bose P, Rahmani M, Grant S. Coordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget 3(12):1499-500, 2012. PMID: 23439314.
Bose P, Grant S. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?. Expert Rev Hematol 5(5):475-8, 2012. PMID: 23146050.

Abstracts

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Claire Harrison, Prithviraj Bose, Raajit K Rampal, Francesca Palandri, Timothy Devos, Francesco Passamonti, Gabriela Hobbs, Moshe Talpaz, Alessandro Vannucchi, Jean-Jacques Kiladjian, Srdan Verstovsek, Ron Hoffman, Mohamed E Salama, Dong Chen, Pietro Taverna, Alex Chang, Gozde Colak, Sandra Klein, Vikas Gupta.. BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY. Hemasphere 6(S1), 2022.
Sangeetha Venugopal, Hui Song, Chingyi Young, Michael A. Cutherell, Janna A. Baganz, Steven Zatorsky, Scott Eric Woodman, Naveen Pemmaraju, Prithviraj Bose, Lucia Masarova, Lingsha Zhou, Sherry Pierce, Hagop Kantarjian, Srdan Verstovsek. OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES. Hemasphere 6(S1), 2022.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Helen Chifotides, Lingsha Zhou, Zeev Estrov, Hagop Kantarjian, Srdan Verstovsek. OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER. Hemasphere 6(S1), 2022.
Daniel J. DeAngelo, Vinod Pullarkat, Miguel Piris-Villaespesa, Tracy I. George, Jay L. Patel, Celalettin Ustun, Prithviraj Bose, Mark L. Heaney, Amanda Pilla, Monica Massaro, Ben Exter, Hina A. Jolin, Zamaneh Mikhak, Tsewang Tashi.. A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS. Hemasphere 6(S1), 2022.
Claire Harrison, Prithviraj Bose, Ruben Mesa, Aaron Gerds, Stephen Oh, Jean-Jacques Kiladjian, Valentin García-Gutierrez, Alessandro Vannucchi, Christof Scheid, Marta Sobas, Srdan Verstovsek, Sarah Buckley, Karisse Roman-Torres, John Mascarenhas. RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA. Hemasphere 6(S1), 2022.
Natalia Curto-Garcia, Marina Kremyanskaya, John Mascarenhas, Francesca Palandri, Alessandro M. Vannucchi, Srdan Verstovsek, Claire Harrison, Prithviraj Bose, Gary J. Schiller, Raajit Rampal, Mark W. Drummond, Vikas Gupta, Andrea Patriarca, Nikki Granacher, Joseph Scandura, Witold Prejzner, Lino L. Teichmann, Ronald Hoffman, Gozde Colak, Zheng Ren, Suresh Bobba, Jike Cui, Sergey Efuni, Moshe Talpaz, Adam J. Mead.. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis—update of clinical and translational data from the ongoing MANIFEST trial. Br J Haematol 197(S1), 2022.
Ruben Mesa, Jeanne Palmer, Prithviraj Bose, Stephen Oh, Raajit Rampal, Sarah Buckley, Karisse Roman-Torres, Srdan Verstovsek, John Mascarenhas.. Symptom Burden in Patients with Myelofibrosis who Have Moderate or Severe Thrombocytopenia: a Retrospective Analysis of Patients Enrolled in the PERSIST-2 Study. J Natl Compr Canc Netw 20(3.5), 2022.
Shehab Fareed Mohamed, Rita Assi, Jing Ning, Lianchun Xiao, Elias J. Jabbour Naveen Pemmaraju, Tapan M. Kadia, Nitin Jain, Courtney D. DiNardo, Musa Yilmaz, Abhishek Maiti, Ghayas C. Issa, Nicholas J. Short, Prithviraj Bose, Lucia Masarova, Guillermo Garcia-Manero, Farhad Ravandi, Marina Konopleva, Hagop Kantarjian, and Naval Daver.. Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. Blood 138(Supplement 1), 2021.
Alexandre Bazinet, Hagop Kantarjian, Gautam Borthakur, Musa Yilmaz, Prithviraj Bose, Elias J. Jabbour, Yesid Alvarado, Kelly S. Chien, Naveen Pemmaraju, Koichi Takahashi, Nicholas J. Short, Ghayas C. Issa, Nitin Jain, Alessandra Ferrajoli, Jan A. Burger, Debra Bull Linderman, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Guillermo Garcia-Manero, Koji Sasaki, Farhad Ravandi, and Tapan M. Kadia. A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. Blood 138(Supplement 1), 2021.
Abhishek Maiti, Courtney D. DiNardo, Caitlin R. Rausch, Naveen Pemmaraju, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Yesid Alvarado, Tapan M. Kadia, Nicholas J. Short, Elias J. Jabbour, Guillermo Montalban-Bravo, Nitin Jain, Steven M. Kornblau, Lucia Masarova, William G. Wierda, Koji Sasaki, Koichi Takahashi, Musa Yilmaz, Jan A. Burger, Zeev E. Estrov, Srdan Verstovsek, Michael Andreeff, Prithviraj Bose, Alessandra Ferrajoli, Philip A. Thompson, Kathryn Montalbano, Kenneth Vaughan, Carol A. Bivins, Sherry A. Pierce, Wei Qiao, Jing Ning, John Welch, Hagop Kantarjian, and Marina Konopleva.. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood 138(Supplement 1), 2021.
Nitin Jain, MD, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Koji Sasaki, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias J. Jabbour, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, and William G. Wierda.. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results. Blood 138(Supplement 1), 2021.
Koji Sasaki, Elias J. Jabbour, Ghayas C. Issa, Kiran Naqvi, Jeffrey Skinner, Kristin Anderson, Sara E Dellasala, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip A. Thompson, Yesid Alvarado, Nitin Jain, Guillermo Garcia-Manero, Koichi Takahashi, Jan A. Burger, Gautam Borthakur, Naveen Pemmaraju, Fadi Haddad, Maria R Khouri, Shilpa Paul, Sherry A. Pierce, Jorge E. Cortes, and Hagop Kantarjian.. Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood 138(Supplement 1), 2021.
Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D. Bledsoe, Naval Daver, Elias J. Jabbour, Tapan M. Kadia, Zeev E. Estrov, Steven M. Kornblau, Michael Andreeff, Jorge E. Cortes, Nitin Jain, Gautam Borthakur, Yesid Alvarado, Julie Huynh-Lu, Madeleine M. Nguyen-Cao, Mary Ann Richie, Mackenzie H. Dobbins, Selene Andrea McCrackin, Lingsha Zhou, Sherry A. Pierce, Xuemei Wang, Allison M. Pike, Guillermo Garcia-Manero, Hagop Kantarjian, and Srdan Verstovsek.. Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. Blood 138(Supplement 1), 2021.
Abhishek Maiti, Courtney D. DiNardo, Caitlin R. Rausch, Naveen Pemmaraju, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Yesid Alvarado, Tapan M. Kadia, Elias J. Jabbour, Nicholas J. Short, Guillermo Montalban-Bravo, Nitin Jain, Steven M. Kornblau, Lucia Masarova, William G. Wierda, Koji Sasaki, Koichi Takahashi, Musa Yilmaz, Jan A. Burger, Zeev E. Estrov, Srdan Verstovsek, Michael Andreeff, Prithviraj Bose, Alessandra Ferrajoli, Philip A. Thompson, Kathryn Montalbano, Kenneth Vaughan, Carol A. Bivins, Sherry A. Pierce, Wei Qiao, Jing Ning, John S. Welch, Hagop Kantarjian, and Marina Konopleva.. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood 138(Supplement 1), 2021.
Nicholas J. Short, Guillermo Montalban-Bravo, Yesid Alvarado, Marina Konopleva, Elias J. Jabbour, Guillermo Garcia-Manero, Musa Yilmaz, Nitin Jain, Gautam Borthakur, Courtney D. DiNardo, Naval Daver, Ghayas C. Issa, Maro Ohanian, Naveen Pemmaraju, Koji Sasaki, Abhishek Maiti, Kelly S. Chien, Farhad Ravandi, Tapan M. Kadia, Michael Andreeff, Muharrem Muftuoglu, Ricardo Delumpa, Prithviraj Bose, Sherry A. Pierce, Lourdes Waller, Glenda Banks, Hagop Kantarjian, and Jorge E. Cortes.. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood 138(Supplement 1), 2021.
Philip A. Thompson, Yan Wang, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Chongjuan Wei, Ana Ayala, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, and William G. Wierda.. Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease. Blood 138(Supplement 1), 2021.
Jeanne M. Palmer, Ruben A. Mesa, Stephen T. Oh, Raajit Rampal, Sarah A Buckley, Karisse Roman-Torres, Srdan Verstovsek, John Mascarenhas, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Claire N. Harrison, Prithviraj Bose, Adam R Craig, and Aaron T. Gerds.. The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study. Blood 138(Supplement 1), 2021.
John Mascarenhas, Prithviraj Bose, Jean-Jacques Kiladjian, Ruben A. Mesa, Aaron T. Gerds, Vikas Gupta, Claire N. Harrison, Abdulraheem Yacoub, Valentín Garcia Gutierrez, Alessandro M. Vannucchi, Christof Scheid, Patricia Velez Tenza, Sarah A Buckley, Karisse Roman-Torres, Stephen T. Oh, Marta Sobas, David Lavie and Srdan Verstovsek.. A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia. Blood 138(Supplement 1), 2021.
Prithviraj Bose, Taghi Manshouri, Sharon D. Bledsoe, Nitin Jain, Lucia Masarova, Naveen Pemmaraju, Nakiuda Hall, Mary Ann Richie, Xuemei Wang, Hagop Kantarjian, Zeev E. Estrov, and Srdan Verstovsek.. A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis. Blood 138(Supplement 1), 2021.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry A. Pierce, Zeev E. Estrov, Hagop Kantarjian, and Srdan Verstovsek.. Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils. Blood 138(Supplement 1), 2021.
Jason Gotlib, Tracy I. George, Michael W. Deininger, Tsewang Tashi, Vinod A. Pullarkat, Prithviraj Bose, Francis Payumo, Amanda Pilla, Hina Jolin, Jessica Sachs, and Daniel J. DeAngelo.. A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM). Blood 138(Supplement 1), 2021.
Marina Kremyanskaya, John Mascarenhas, Francesca Palandri, Alessandro Vannucchi, Srdan Verstovsek, Claire N. Harrison, Prithviraj Bose, Gary J. Schiller, Raajit Rampal, Mark W. Drummond, Vikas Gupta, Andrea Patriarca, Nikki Granacher, Joseph Scandura, Witold Prejzner, Lino L. Teichmann, Natalia Curto-Garcia, Ronald Hoffman, Gozde Colak, Zheng Ren, Suresh Bobba, Jike Cui, Sergey Efuni, and Moshe Talpaz.. Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis – Update of Clinical and Translational Data from the Ongoing Manifest Trial. Blood 138(Supplement 1), 2021.
Andreas Reiter, Daniel J. DeAngelo, Deepti Radia, Michael W. Deininger, Tracy I. George, Jens Panse, Alessandro M. Vannucchi, Madlen Jentzsch, Iván Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lisa K. Hicks, Lambert Span, Ruben Mesa, Prithviraj Bose, Kristen M. Pettit, Mark L. Heaney, Stephen Oh, Jayita Sen, Hui-Min Lin, Brenton G. Mar, Jason Gotlib. EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY. Hemasphere 5(S1), 2021.
Srdan Verstovsek, Marina Kremyanskaya, John Mascarenhas, Moshe Talpaz, Claire Harrison, Raajit Rampal, Andrea Patriarca, Vikas Gupta, Nikki Granacher, Tim Somervaille, Gary Schiller, Mark Drummond, Linda Foltz, Jonathan Lambert, Witold Prejzner, Gozde Colak, Patricia Keller, James Shao, Katarina Luptakova, Ronald Hoffman, Prithviraj Bose, Alessandro Vannucchi.. PELABRESIB (CPI-0610) IMPROVED ANEMIA ASSOCIATED WITH MYELOFIBROSIS: INTERIM RESULTS FROM MANIFEST PHASE 2 STUDY. Hemasphere 5(S1), 2021.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Helen Chifotides, Lingsha Zhou, Zeev Estrov, Hagop Kantarjian, Srdan Verstovsek. OVERALL AND CAUSE SPECIFIC CHANGES IN MORTALITY OF PATIENTS WITH MYELOFIBROSIS OVER THE LAST 3 DECADES. Hemasphere 5(S1), 2021.
Marina Kremyanskaya, John Mascarenhas, Andrea Patriarca, Vikas Gupta, Timothy Devos, Claire Harrison, Francesco Passamonti, Raajit Rampal, Adam Mead, Joseph Scandura, Gabriela Hobbs, Moshe Talpaz, Nikki Granacher, Tim Somervaille, Ronald Hoffman, Prithviraj Bose, Gozde Colak, James Shao, Jike Cui, Suresh Bobba, Katarina Luptakova, Srdan Verstovsek, Francesca Palandri.. CLINICAL BENEFIT OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: INTERIM EFFICACY SUBGROUP ANALYSIS FROM ARM 3 OF MANIFEST PH2 STUDY. Hemasphere 5(S1), 2021.
Daniel J. DeAngelo, Andreas Reiter, Deepti Radia, Michael W. Deininger, Tracy I. George, Jens Panse, Alessandro M. Vannucchi, Madlen Jentzsch, Iván Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lisa K. Hicks, Lambert Span, Ruben Mesa, Prithviraj Bose, Kristen M. Pettit, Mark L. Heaney, Stephen Oh, Jayita Sen, Hui-Min Lin, Brenton G. Mar, Jason Gotlib. PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM). Clin Cancer Res, 2021.
Curtis Andrew Lachowiez, Gautam Borthakur, Sanam Loghavi, Zhihong Zeng, Tapan M. Kadia, Lucia Masarova, Koichi Takahashi, George Dono Tippett, Samantha Smith, Jacqueline Suen Garcia, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Naval Guastad Daver, Guillermo Garcia-Manero, Bilyana Stoilova, Paresh Vyas, Hagop M. Kantarjian, Marina Konopleva, Courtney Denton Dinardo.. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. J Clin Oncol 39(suppl 15), 2021.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Koji Sasaki, Helen Chifotides, Lingsha Zhou, Hagop Kantarjian, Zeev Estrov, Srdan Verstovsek. Improved Survival of Patients with Primary Myelofibrosis in the Last Decade at a Large Single Academic Center. Clin Lymphoma Myeloma Leuk 21(S1):S361, 2021.
Prithviraj Bose, Srdan Verstovsek, Marina Kremyanskaya, John Mascarenhas, Moshe Talpaz, Claire Harrison, Raajit Rampal, Andrea Patriarca, Vikas Gupta, Nikki Granacher, Tim Somervaille, Gary Schiller, Mark Drummond, Linda Foltz, Jonathan Lambert, Witold Prejzner, Gozde Colak, Patricia Keller, James Shao, Katarina Luptakova, Ronald Hoffman, Alessandro Vannucchi.. Pelabresib (CPI-0610) Improved Anemia Associated With Myelofibrosis: Interim Results From Ongoing MANIFEST Phase 2 Study. Clin Lymphoma Myeloma Leuk 21(S1):S361-2, 2021.
Vikas Gupta, Marina Kremyanskaya, John Mascarenhas, Francesca Palandri, Andrea Patriarca, Timothy Devios, Claire Harrison, Francesco Passamonti, Raajit Rampal, Adam Mead, Joseph Scandura, Gabriela Hobbs, Moshe Talpaz, Nikki Granacher, Tim Somervaille, Ronald Hoffman, Prithviraj Bose, Gozde Colak, James Shao, Jike Cui, Suresh Bobba, Katarina Luptakova, Srdan Verstovsek.. Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study. Clin Lymphoma Myeloma Leuk 21(S1):S362, 2021.
Nicholas J. Short, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Gautam Borthakur, Guillermo Garcia-Manero, Elias Jabbour, Koji Sasaki, Ghayas C. Issa, Guillermo Montalban-Bravo, Prithviraj Bose, Jan A. Burger, Darla Miller, Lynette Alexander-Williams, Farhad Ravandi, Marina Konopleva, Hagop M. Kantarjian, and Naval Daver.. Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. Blood 136, 2020.
Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Koji Sasaki, Nathan H Fowler, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, and William G. Wierda.. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood 136, 2020.
Patrick K Reville, Hagop M. Kantarjian, Gautam Borthakur, Musa Yilmaz, Guillermo Montalban-Bravo, Courtney D. DiNardo, Michael Andreeff, MD, Naval Daver, Nitin Jain, Steven M. Kornblau, Elias Jabbour, Nicholas J. Short, Yesid Alvarado, Maro Ohanian, Prithviraj Bose, Lucia Masarova, Sa A Wang, Rebecca S. S Tidwell, Zeev E. Estrov, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, and Tapan M. Kadia.. Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 136, 2020.
Kiyomi Morita, Guillermo Montalban Bravo, Koji Sasaki, Kristy R. Bodden, Feng Wang, Prithviraj Bose, Yesid Alvarado, Naval Daver, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Elias Jabbour, Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Maro Ohanian, Sherry A. Pierce, Mohammad Azab, Hagop M. Kantarjian, and Guillermo Garcia-Manero.. Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 136, 2020.
Abhishek Maiti, Courtney D. DiNardo, Sa A Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver, Nicholas J. Short, Musa Yilmaz, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Alessandra Ferrajoli, Elias Jabbour, Nitin Jain, Guillermo Garcia-Manero, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Lucia Masarova, Jan A. Burger, Philip A. Thompson, Srdan Verstovsek, Koji Sasaki, Michael Andreeff, Caitlin R. Rausch, Kathryn Montalbano, Sherry A. Pierce, Hagop M. Kantarjian, Marina Konopleva, and Farhad Ravandi.. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood 136, 2020.
Philip A. Thompson, Alessandra Ferrajoli, Nitin Jain, Yan Wang, Christine B Peterson, Naveen Garg, Chongjuan Wei, Ana Ayala, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, Michael J. Keating, and William G. Wierda.. The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. Blood 136, 2020.
Prithviraj Bose, Naveen Pemmaraju, Lucia Masarova, Sharon D. Bledsoe, Naval Daver, Elias Jabbour, Tapan M. Kadia, Zeev E. Estrov, Steven M. Kornblau, Michael Andreeff, Jorge E. Cortes, Nitin Jain, Gautam Borthakur, Yesid Alvarado, Julie Huynh-Lu, Madeleine Nguyen-Cao, Mary Ann Richie, Mackenzie H. Dobbins, Lingsha Zhou, Sherry A. Pierce, Xuemei Wang, Allison M. Pike, Guillermo Garcia-Manero, Hagop M. Kantarjian, and Srdan Verstovsek.. Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study. Blood 136, 2020.
Kelly S. Chien, Gautam Borthakur, Kiran Naqvi, Naval Daver, Guillermo Montalban Bravo, Jorge E. Cortes, Courtney D. DiNardo, Elias Jabbour, Yesid Alvarado, Michael Andreeff, Prithviraj Bose, Nitin Jain, Kimberly Sheppard, Cheri Klingner-Winton, Sherry A. Pierce, Xiao Qin Dong, Kelly A. Soltysiak, Hagop M. Kantarjian, and Guillermo Garcia-Manero.. Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome. Blood 136, 2020.
Koji Sasaki, Elias Jabbour, Kiran Naqvi, Jeffrey Skinner, Kristin Anderson, Sara E Dellasala, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip A. Thompson, Yesid Alvarado, Nitin Jain, Guillermo Garcia-Manero, Koichi Takahashi, Jan A. Burger, Gautam Borthakur, Naveen Pemmaraju, Rita Khouri Shilpa Paul, Sherry A. Pierce, Jorge E. Cortes, and Hagop M. Kantarjian.. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Blood 136, 2020.
Kelly S. Chien, Gautam Borthakur, Kiran Naqvi, Naval Daver, Guillermo Montalban Bravo, Jorge E. Cortes, Courtney D. DiNardo, Elias Jabbour, Yesid Alvarado, Michael Andreeff, Prithviraj Bose, Nitin Jain, Kimberly Sheppard, Cheri Klingner-Winton, Sherry A. Pierce, Xiao Qin Dong, Kelly A. Soltysiak, Hagop M. Kantarjian, and Guillermo Garcia-Manero.. Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy. Blood 136, 2020.
Abhishek Maiti, Elias Jabbour, Nitin Jain, Gautam Borthakur, Tapan M. Kadia, Jan A. Burger, William G. Wierda, Marina Konopleva, Yesid Alvarado, Nicholas J. Short, Stefan Faderl, Susan M. O'Brien, Alessandra Ferrajoli, Steven M. Kornblau, Naval Daver, Naveen Pemmaraju, Prithviraj Bose, Philip A. Thompson, Joseph D. Khoury, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, Guillermo Garcia-Manero, Hagop M. Kantarjian, and Farhad Ravandi.. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood 136, 2020.
Kiyomi Morita, Hagop M. Kantarjian, Guillermo Montalban Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Kelly S. Chien, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Konopleva, Caitlin R. Rausch, Yvonne Gasior, and Guillermo Garcia-Manero.. A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 136, 2020.
Kunhwa Kim, Abhishek Maiti, Tapan M. Kadia, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Nicholas J. Short, Musa Yilmaz, Yesid Alvarado, Alessandra Ferrajoli, Elias Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A. Thompson, Caitlin R. Rausch, Kathryn Montalbano, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Hagop M. Kantarjian, Courtney D. DiNardo, and Marina Konopleva.. Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood 136, 2020.
Abhishek Maiti, Sergej Konoplev, Courtney D. DiNardo, Tapan M. Kadia, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Nicholas J. Short, Musa Yilmaz, Yesid Alvarado, Alessandra Ferrajoli, Elias Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A. Thompson, Caitlin R. Rausch, Kathryn Montalbano, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Hagop M. Kantarjian, and Marina Konopleva.. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. Blood 136, 2020.
Daniel Rivera, Srdan Verstovsek, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry A. Pierce, Hagop M. Kantarjian, Zeev E. Estrov, and Lucia Masarova.. Outcomes of Patients with Myelofibrosis and Favorable Karyotype. Blood 136, 2020.
Sangeetha Venugopal, Srdan Verstovsek, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry A. Pierce, Hagop M. Kantarjian, Zeev E. Estrov, and Lucia Masarova.. Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms. Blood 136, 2020.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry A. Pierce, Zeev E. Estrov, Hagop M. Kantarjian and Srdan Verstovsek.. Improved Survival of Patients with Myelofibrosis in the Last Decade. Blood 136, 2020.
Srdan Verstovsek, John Mascarenhas, Marina Kremyanskaya, Ronald Hoffman, Raajit K. Rampal, Vikas Gupta, Moshe Talpaz, Nikki Granacher, Brian Leber, Jean-Jacques Kiladjian, Alessandro Vannucchi, Prithviraj Bose, Mary Frances McMullin, Shireen Sirhan, Vincent Ribrag, Katarina Luptakova, Jessica Christo, Jing Wang, Jennifer A Mertz, Gozde Colak, James Shao, Suresh Bobba, , Patrick Trojer, Adrian Senderowicz, and Claire Harrison.. CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study. Blood 136, 2020.
Moshe Talpaz, Raajit K. Rampal, Srdan Verstovsek, Claire Harrison, Mark W. Drummond, Jean-Jacques Kiladjian, Alessandro Vannucchi, Marina Kremyanskaya, Gary J. Schiller, Andrea Patriarca, Gwendolyn Van Gorkom, Prithviraj Bose, Ronald Hoffman, Katarina Luptakova, Jessica Christo, Jing Wang, Jennifer A Mertz, Gozde Colak, James Shao, Suresh Bobba, Patrick Trojer, Adrian Senderowicz, and John Mascarenhas.. CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As Monotherapy in Advanced Myelofibrosis Patients Refractory/Intolerant to JAK Inhibitor: Update from Phase 2 MANIFEST Study. Blood 136, 2020.
Guillermo Montalban Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Lucia Masarova, Kiran Naqvi, Elias Jabbour, Courtney D. DiNardo, Koichi Takahashi, Marina Konopleva, Naveen Pemmaraju, Nicholas J. Short, Ghayas C. Issa, Tapan M. Kadia, Farhad Ravandi, Naval Daver, Gautam Borthakur, Zeev E. Estrov, Joseph D. Khoury, Sanam Loghavi, Sherry A. Pierce, Carlos E. Bueso-Ramos, Keyur Patel, Srdan Verstovsek, Hagop M. Kantarjian, Prithviraj Bose, and Guillermo Garcia-Manero.. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. Blood 136, 2020.
Hind Rafei, Hagop M. Kantarjian, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Joseph D. Khoury, Sa A Wang, Jeffrey L. Jorgensen, Issa F. Khouri, Partow Kebriaei, Nitin Jain, Bouthaina S. Dabaja, Lucia Masarova, Tapan M. Kadia, Shilpa Paul, Dan Nichols, Guillermo Garcia-Manero, Jan A. Burger, Courtney D. DiNardo, Naval Daver, Guillermo Montalban-Bravo, Musa Yilmaz, Prithviraj Bose, Rita Khouri, Philip A. Thompson, Jovitta Jacob, Meagan Rostykus , Rebecca Garris, Marina Konopleva, Susan M. O'Brien, and Elias Jabbour.. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood 136, 2020.
Abhishek Maiti, Courtney D. DiNardo, Farhad Ravandi, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Tapan M. Kadia, Nicholas J. Short, Musa Yilmaz, Guillermo Montalban-Bravo, Alessandra Ferrajoli, Elias Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A. Thompson, Caitlin R. Rausch, Kathryn S Montalbano, Sherry A. Pierce, Hagop M. Kantarjian, Naval Daver, and Marina Konopleva.. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. Blood 136, 2020.
Warren Fiskus, Christopher Peter Mill, Christine Birdwell, Bernardo H Lara, Prithviraj Bose, Lucia Masarova, Tapan M. Kadia, Joseph D. Khoury, Taghi Manshouri, Srdan Verstovsek, and Kapil N. Bhalla.. Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells. Blood 136, 2020.
Jason Gotlib, Deepti H. Radia, Tracy I. George, William A Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott F. Winton, Hans-Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica K. Evans, Hui-Min Lin, Brenton G. Mar, Michael W. Deininger, and Daniel J. DeAngelo.. Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. Blood 136, 2020.
Caitlin R. Rausch, Adam DiPippo, Prithviraj Bose, and Dimitrios P. Kontoyiannis.. Breakthrough Invasive Fungal Infections (bIFI) Are Uncommon in Patients with Newly Diagnosed Acute Leukemia Receiving Primary Antifungal Prophylaxis. Blood 136, 2020.
Jason Gotlib, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Jr., Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott Winton, Hans-Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica K. Evans, Hui-Min Lin, Brenton G. Mar, Michael W. Deininger, Daniel J. DeAngelo.. AVAPRITINIB INDUCES RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), REGARDLESS OF PRIOR MIDOSTAURIN THERAPY. Hemasphere 4(S1), 2020.
Srdan Verstovsek, John Mascarenhas, Marina Kremyanskaya, Ronald Hoffman, Raajit Rampal, Vikas Gupta, Moshe Talpaz, Nikki Granacher, Brian Leber, Jean-Jaques Kiladjian, Alessandro Vannucchi, Prithviraj Bose, Mary McMullin, Shireen Sirhan, Vincent Ribrag, Sujan Kabir, Jennifer Mertz, Gozde Colak, James Shao, Suresh Bobba, Patrick Trojer, Adrian Senderowicz, Claire Harrison.. CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS 'ADD-ON' TO RUXOLITINIB (RUX), IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY. Hemasphere 4(S1), 2020.
Moshe Talpaz, Raajit Rampal, Srdan Verstovsek, Claire Harrison, Mark Drummond, Jean-Jaques Kiladjian, Alessandro Vannucchi, Marina Kremyanskaya, Gary Schiller, Andrea Patriarca, Gwendolyn Van Gorkom, Prithviraj Bose, Ronald Hoffman, Sujan Kabir, Jennifer Mertz, Gozde Colak, James Shao, Suresh Bobba, Patrick Trojer, Adrian Senderowicz, John Mascarenhas.. CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY. Hemasphere 4(S1), 2020.
Courtney DiNardo, Curtis Lachowiez, Gautam Borthakur, Sanam Loghavi, Zhihong Zeng, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Kiran Naqvi, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Naval Daver, Guillermo Garcia-Manero, Bilyana Stoilova, Paresh Vyas, Hagop Kantarjian, Marina Konopleva.. PHASE IB/II STUDY OF THE IDH1-MUTANT INHIBITOR IVOSIDENIB WITH THE BCL2 INHIBITOR VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED HEMATOLOGIC MALIGNANCIES. Hemasphere 4(S1), 2020.
Abhishek Maiti, Courtney DiNardo, Tapan Kadia, Caitlin Rausch, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Kiran Naqvi, Maro Ohanian, Nicholas Short, Yesid Alvarado, Koichi Takahashi, Musa Yilmaz, Nitin Jain, Steven Kornblau, Koji Sasaki, Michael Andreeff, Prithviraj Bose, Alessandra Ferrajoli, Ghayas Issa, Elias Jabbour, Lucia Masarova, Philip Thompson, Sherry Pierce, Guillermo Garcia-Manero, Farhad Ravandi, John Welch, Wei Qiao, Jing Ning, Hagop Kantarjian, Marina Konopleva.. Intensive Chemotherapy (IC) In Acute Myeloid Leukemia (AML): A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Hemasphere 4(S1), 2020.
Curtis Andrew Lachowiez, Gautam Borthakur, Sanam Loghavi, Zhihong Zeng, Tapan M. Kadia, Lucia Masarova, Koichi Takahashi, George Dono Tippett, Kiran Naqvi, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Naval Guastad Daver, Guillermo Garcia-Manero, Bilyana Stoilova, Paresh Vyas, Hagop M. Kantarjian, Marina Konopleva, Courtney Denton Dinardo, Anna B. Halpern.. Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. J Clin Oncol 38 (suppl), 2020.
Tapan M. Kadia, Guillermo Garcia-Manero, Musa Yilmaz, Courtney Denton Dinardo, Marina Konopleva, Guillermo Montalban-Bravo, Gautam Borthakur, Elias Jabbour, Nitin Jain, Michael Andreeff, Nicholas James Short, Ghayas C. Issa, Maro Ohanian, Prithviraj Bose, Naval Guastad Daver, Sa A Wang, Rebecca Tidwell, Zeev Estrov, Farhad Ravandi, Hagop M. Kantarjian.. Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 38 (suppl), 2020.
Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD, PhD, Jeffrey L. Jorgensen, MD, PhD, Sa A Wang, MD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Michael J Keating, MBBS and William G. Wierda, MD, PhD.. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood 134:357, 2019.
Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MD, MPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD, PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD, PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD, PhD, Courtney D. DiNardo, MD, MSc. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood 134:645, 2019.
Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MD, MPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD, PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD, PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD, PhD, Courtney D. DiNardo, MD, MSc. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood 134:738, 2019.
Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD, PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD, MSc, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD, PhD, Jeffrey L. Jorgensen, MD, PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD, PhD.. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134:34, 2019.
Abhishek Maiti, MBBS, Courtney D. DiNardo, MD, MSc, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MD, MPH, Maro N. Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD, PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD, PhD, Hagop M. Kantarjian, MD and Marina Y Konopleva, MD, PhD. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood 134:2637, 2019.
Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MD, MPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MD, MSc, Elias Jabbour, MD, Michael Andreeff, MD, PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD. Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Blood 134:4240, 2019.
Raajit K. Rampal, MD, PhD, Srdan Verstovsek, MD, PhD, Sean M. Devlin, PhD, Amber C. King, PharmD, BCOP, Eytan M. Stein, MD, Naveen Pemmaraju, MD, Michael J. Mauro, MD, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose, MD. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood 134:4163, 2019.
Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Lucia Masarova, MD, Naveen Pemmaraju, MD, Elias Jabbour, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, MSc, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Gautam M. Borthakur, MD, William G. Wierda, MD, PhD, Alessandra Ferrajoli, MD, Koji Sasaki, MD, Koichi Takahashi, MD, Kiran Naqvi, MD, MPH, Yesid Alvarado, MD, Maro N. Ohanian, DO, Nitin Jain, MD, Prithviraj Bose, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD, PhD, Zeev E. Estrov, MD, Srdan Verstovsek, MD, PhD, Naval G. Daver, MD. A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood 134:4237, 2019.
Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MBBS, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Prithviraj Bose, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Marina Y Konopleva, MD, PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD, MSc, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD, PhD, Jeffrey L. Jorgensen, MD, PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD, PhD. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood 134:359, 2019.
Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Xuemei Wang, MS, Joseph D. Khoury, MD, Farhad Ravandi, MD, Jeffrey L. Jorgensen, MD, PhD, Nicholas J. Short, MD, Sanam Loghavi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Koji Sasaki, MD, Marina Y Konopleva, MD, PhD, Koichi Takahashi, MD, William G. Wierda, MD, PhD, Nitin Jain, MD, Srdan Verstovsek, MD, PhD, Zeev E. Estrov, MD, Prithviraj Bose, MD, Sherry A. Pierce, BSN, BA, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood 134:1297, 2019.
John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD, FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD, PhD. MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or “Add-on” to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood 134:670, 2019.
Uri Rozovski, MD, David M. Harris, PhD, Ping Li, PhD, Zhiming Liu, BS, Taghi Manshouri, PhD, Ivo Veletic, MD, Preetesh Jain, MBBS, MD, DM, PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Michael J Keating, MBBS, Zeev E. Estrov, MD. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. Blood 134:3024, 2019.
Uri Rozovski, MD, David M. Harris, PhD, Ping Li, PhD, Zhiming Liu, BS, Taghi Manshouri, PhD, Ivo Veletic, MD, Preetesh Jain, MBBS, MD, DM, PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Michael J Keating, MBBS, Zeev E. Estrov, MD. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. Blood 134:3018, 2019.
Bachar Samra, MD, Guillaume Richard-Carpentier, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Veronica A Guerra, MD, Naval G. Daver, MD, Courtney D. DiNardo, MD, MSc, Ghayas C. Issa, MD, Prithviraj Bose, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Nicholas J. Short. Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood 134:3834, 2019.
Lucia Masarova, MD, Srdan Verstovsek, MD, PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Elias Jabbour, MD, Maro Ohanian, DO, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Romany Gergis, Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, MSc, Farhad Ravandi, MD, Marina Y Konopleva, MD, PhD, Kiran Naqvi, MD, MPH, Koji Sasaki, MD, Zeev E. Estrov, MD, Guillermo Garcia-Manero, MD, Carlos E. Bueso-Ramos, MD, PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD. Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood 134:1656, 2019.
Hagop M. Kantarjian, MD, Guillaume Richard-Carpentier, MD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kiran Naqvi, MD, MPH, Koji Sasaki, MD, Tapan M. Kadia, MD, Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD, MSc, Naveen Pemmaraju, MD, Naval G. Daver, MD, Prithviraj Bose, MD, Sherry A. Pierce, BSN, BA, Samuel Dara, MBBS, Elias Jabbour, Mahran Shoukier, Jorge E. Cortes, MD. Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood 134:2941, 2019.
Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD and William G. Wierda, MD, PhD. Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. Blood 134:358, 2019.
Warren Fiskus, BSc, PhD, Christopher Peter Mill, PhD, BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD, PhD and Kapil N. Bhalla, MD. Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells. Blood 134:1274, 2019.
Naveen Pemmaraju, MD, Bing Z Carter, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Carlos E. Bueso-Ramos, MD, PhD, Courtney D. DiNardo, MD, MSc, Sharon Bledsoe, Naval G. Daver, MD, Uday Popat, MD, Marina Y Konopleva, MD, PhD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Lingsha Zhou, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Po Yee Mak, Nitin Jain, MD, Elias Jabbour, Srdan Verstovsek, MD, PhD. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood 134:555, 2019.
Lik Wee Lee, Travers Ching, Keyur Patel, Philip A. Thompson, Nitin Jain, Alessandra Ferrajoli, Zeev Estrov, Jan Burger, Michael Keating, Prithviraj Bose, William G. Wierda, Ilan Kirsch. Assessment of immunoglobulin heavy chain variable region (IGHV) mutation status with a next-generation sequencing (NGS) immunosequencing assay for minimal residual disease (MRD), 2019.
Nitin Jain, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan Kadia, Naveeen Pemmaraju, Koji Sasaki, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey Jorgensen, Sa Wang, William Plunkett, Varsha Gandhi, Hagop Kantarjian, Susan O’Brien, Michael Keating, William G. Wierda.. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-line Treatment of patients with CLL with Mutated IGHV and without TP53 Aberrations, 2019.
Marina Kremyanskaya, Ronald Hoffman, John Mascarenhas, Prithviraj Bose, Vikas Gupta, Gary J. Schiller, Elena Liew, Claudia Lebedinsky, Adrian Mario Senderowicz, Jennifer Mertz, Patrick Trojer, Srdan Verstovsek. A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF). J Clin Oncol 37(suppl), 2019.
Abhishek Maiti, Farhad Ravandi, Jorge E. Cortes, Elias Jabbour, Kayleigh Marx, Naval Guastad Daver, Guillermo Garcia-Manero, Marina Konopleva, Christopher Brent Benton, Lucia Masarova, Courtney Denton Dinardo, Prithviraj Bose, Kiran Naqvi, Sherry A. Pierce, Hagop M. Kantarjian, Nicholas James Short. Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP). J Clin Oncol 37(suppl), 2019.
Kiran Naqvi, Elias Jabbour, Jeffrey A Skinner, Kristin N Anderson, Musa Yilmaz, Nitin Jain, Alessandra Ferrajoli, Prithviraj Bose, Philip A. Thompson, Yesid Alvarado, Koichi Takahashi, Jan Andreas Burger, Gautam Borthakur, Zeev Estrov, Naveen Pemmaraju, Shilpa Paul, Sara Dellasala, Jorge E. Cortes, Hagop M. Kantarjian. Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP). J Clin Oncol 37(suppl), 2019.
Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Sharon Bledsoe, Tapan Kadia, Zeev Estrov, Steven Kornblau, Gautam Borthakur, Lucia Masarova, Julie Huynh-Lu, Madeleine Henriquez, Mary Ann Richie, Jeannette Sun, Lingsha Zhou, Sherry Pierce, Xuemei Wang, Allison Pike, Hagop Kantarjian, Srdan Verstovsek. SOTATERCEPT (ACE-011) IN SUBJECTS WITH MPN-ASSOCIATED MYELOFIBROSIS AND ANEMIA. Hemasphere 3(suppl 1), 2019.
Prithviraj Bose, Srdan Verstovsek, Kiran Naqvi, Elias Jabbour, Courtney DiNardo, Yesid Alvarado, Naveen Pemmaraju, Naval Daver, Tapan Kadia, Nicholas Short, Nitin Jain, Christopher Benton, Koichi Takahashi, Zeev Estrov, Jorge Cortes, Graciela Nogueras-Gonzalez, Xuelin Huang, John Villareal, Sherry Pierce, Louis Wilson, Susan Tse, Hagop Kantarjian, Farhad Ravandi. PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML). Hemasphere 3(suppl 1), 2019.
Raajit Rampal, Srdan Verstovsek, Sean Devlin, Eytan Stein, Tapan Kadia, Michael Mauro, Naveen Pemmaraju, Guillermo Montalban-Bravo, Amber King, Kelsey Alvarez, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose. EARLY RESULTS OF A PHASE II STUDY OF COMBINED RUXOLITINIB AND THALIDOMIDE IN PATIENTS WITH MYELOFIBROSIS. Hemasphere 3(suppl 1), 2019.
Courtney DiNardo, Koichi Takahashi, Tapan Kadia, Sanam Loghavi, Kiran Naqvi, Prithviraj Bose, Naval Daver, George Donovan Tippett, Gautam Borthakur, Jorge Cortes, Steven Chan, Lynn Quek, Paresh Vyas, Hagop Kantarjian, Marina Konopleva. A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES. Hemasphere 3(suppl 1), 2019.
Deepti Radia, Michael W. Deininger, Jason Gotlib, Prithviraj Bose, Mark W. Drummond, Elizabeth O. Hexner, William A. Robinson, Albert T. Quiery, Tracy I. George, Hans-Peter Horny, Ronny Oren, Hongliang Shi, Oleg Schmidt-Kittler, Brenton Mar, Daniel DeAngelo. AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). Hemasphere 3(suppl 1), 2019.
Ronald Hoffman, John Mascarenhas, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Gary Schiller, Elena Liew, Anna Godfrey, Jennifer Mertz, Jessica Piel, Patrick Trojer, Cludia Lebedinsky, Adrian Senderowicz, Sujan Kabir, Jeffrey Supko, Srdan Verstovsek. CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO-INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS. Hemasphere 3(suppl 1), 2019.
Kiran Naqvi, Elias Jabbour, Jeffrey Skinner, Kristin Anderson, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado, Nitin Jain, Koichi Takahashi, Jan Burger, Zeev Estrov, Gautam Borthakur, Naveen Pemmaraju, Sara Dellasala, Shilpa Paul, Jorge Cortes, Hagop Kantarjian. FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP). Hemasphere 3(suppl 1), 2019.
Prithviraj Bose, David McCue, Nathan P. Wiederhold, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Musa Yilmaz, Koichi Takahashi, Philip A. Thompson, Naveen Pemmaraju, Naval G. Daver, Jan A. Burger, Jorge E. Cortes, Guillermo Garcia-Manero, Srdan Verstovsek, Marina Y. Konopleva, Nitin Jain, Courtney D. DiNardo, Yesid Alvarado, Kiran Naqvi, Steven M. Kornblau, Alessandra Ferrajoli, William G. Wierda, Zeev E. Estrov, Christopher B. Benton, Lucia Masarova, Guillermo Montalban-Bravo, Koji Sasaki, Caitlin R. Rausch, Kayleigh Marx, Wei Qiao, Xuelin Huang, Carol A. Bivins, Sherry A. Pierce, Hagop M. Kantarjian, Dimitrios P. Kontoyiannis. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132, 2018.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Zeev E. Estrov, Lingsha Zhou, Sherry A. Pierce, Jorge E. Cortes, Hagop M. Kantarjian, Srdan Verstovsek. Evaluation of Cytogenetic Stratifications in Myelofibrosis. Blood 132, 2018.
Raajit K. Rampal, Srdan Verstovsek, Sean M Devlin, Eytan M. Stein, Tapan M. Kadia, Michael J. Mauro, Naveen Pemmaraju, Kelsey Alvarez, Nicole Ard, Tawni Goodman, Kelly Marek, Prithviraj Bose. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study. Blood 132, 2018.
Lucia Masarova, Srdan Verstovsek, Jorge E. Cortes, Naveen Pemmaraju, Prithviraj Bose, Maro N. Ohanian, Lingsha Zhou, Sherry A. Pierce, Romany Gergis, Gautam Borthakur, Zeev E. Estrov, Guillermo Garcia-Manero, Hagop M. Kantarjian and Naval G. Daver. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132, 2018.
Uri Rozovski, Ping Li, David M. Harris, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Prithviraj Bose, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating and Zeev E. Estrov. Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage. Blood 132, 2018.
Fevzi Yalniz, Hagop M. Kantarjian, Gautam Borthakur, Tapan M. Kadia, Naval G. Daver, Naveen Pemmaraju, Marina Y. Konopleva, Guillermo Garcia-Manero, Koichi Takahashi, Courtney D. DiNardo, Prithviraj Bose, Michael Andreeff, Farhad Ravandi and Jorge E. Cortes. Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. Blood 132, 2018.
Uri Rozovski, David M. Harris, Ping Li, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Prithviraj Bose, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating and Zeev E. Estrov. CLL Cells with 13q- Are Characterized By High BCL2 Levels and CLL Cells with Trisomy-12 By Increased Activation of STAT3 and NF-κB. Blood 132, 2018.
Fevzi Yalniz, Hagop M. Kantarjian, Tapan M. Kadia, Guillermo Garcia-Manero, Keyur Patel, Sanam Loghavi, Koji Sasaki, Naval G. Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J Short, Musa Yilmaz, Prithviraj Bose, Kiran Naqvi, Sherry A. Pierce, Jorge E. Cortes and Farhad Ravandi. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood 132, 2018.
Darwin Roman, Hagop M. Kantarjian, Jorge E. Cortes, Gautam Borthakur, Guillermo Garcia-Manero, Marina Y. Konopleva, Courtney D. DiNardo, Naval G. Daver, Naveen Pemmaraju, Tapan M. Kadia, Steven M. Kornblau, Prithviraj Bose, Michael Andreeff, Emil J. Freireich, Farhad Ravandi and Fleur M. Aung. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood 132, 2018.
Jason R. Gotlib, Deepti Radia, Daniel J. DeAngelo, Prithviraj Bose, Mark W Drummond, Elizabeth O. Hexner, William A Robinson, Maureen G. Conlan, Ronny G. Oren, Hongliang Shi and Michael W. Deininger. Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood 132, 2018.
Mansour Alfayez, Hagop M. Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Marina Y. Konopleva, Naval G. Daver, Courtney D. DiNardo, Gautam Borthakur, Prithviraj Bose, Michael Andreeff, Yesid Alvarado, Musa E. Yilmaz, Naveen Pemmaraju, Steven M. Kornblau, Zeev E. Estrov, Christopher B. Benton, Koichi Takahashi, Kiran Naqvi, Rebecca Slack, Rubiul Islam, Elias J. Jabbour, Jorge E. Cortes and Tapan M. Kadia. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 132, 2018.
Caitlin R. Rausch, Shilpa Paul, Guillermo Montalban Bravo, Elias J. Jabbour, Naval G. Daver, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Steven M. Kornblau, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Maro N. Ohanian, Sherry A. Pierce, Yvonne Gasior, Christopher B. Benton, Nitin Jain, Koichi Takahashi, Lucia Masarova, Michael Andreeff, Zeev E. Estrov, Hagop M. Kantarjian and Guillermo Garcia-Manero. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 132, 2018.
Mansour Alfayez, Hagop M. Kantarjian, Nicholas J Short, Rita Assi, Maria Khouri, Farhad Ravandi, Shilpa Paul, Caitlin R. Rausch, Patrice Nasnas, Gautam Borthakur, Courtney D. DiNardo, Tapan M. Kadia, Naval G. Daver, Guillermo Garcia-Manero, Kiran Naqvi, Prithviraj Bose, Susan M. O'Brien, Jorge E. Cortes and Elias J. Jabbour. Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood 132, 2018.
Guillermo Garcia-Manero, Elias J. Jabbour, Marina Y. Konopleva, Naval G. Daver, Gautam Borthakur, Courtney D. DiNardo, Prithviraj Bose, Parita Patel, Rami S. Komrokji, Aditi Shastri, Gail J. Roboz, Robert Matthew Miller, Sarah Arbe-Barnes, Mary Reilly, Peter McGuirk, Tara Kearney, Brian Keogh and Hagop M. Kantarjian. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood 132, 2018.
Guillaume Richard-Carpentier, Hagop M. Kantarjian, Farhad Ravandi, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Courtney D. DiNardo, William G. Wierda, Naval G. Daver, Naveen Pemmaraju, Prithviraj Bose, Marina Y. Konopleva, Michael Andreeff, Srdan Verstovsek, Heidi M Krause, Fleur M. Aung and Jorge E. Cortes. Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients. Blood 132, 2018.
Eran Tallis, Hagop M. Kantarjian, Catherine Kendall Major, Maria Vazquez, Gautam Borthakur, Prithviraj Bose, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Alessandra Ferrajoli, Naveen Pemmaraju, Naval G. Daver, Courtney D. DiNardo, Marina Y. Konopleva, Steven M. Kornblau, Richard E Champlin, Elias J. Jabbour, Sherry A. Pierce and Jorge E. Cortes. Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs. Blood 132, 2018.
Tapan M. Kadia, Marina Y. Konopleva, Guillermo Garcia-Manero, Christopher B. Benton, William G. Wierda, Prithviraj Bose, Musa E. Yilmaz, Elias J. Jabbour, Steven M. Kornblau, Kapil N. Bhalla, Naveen Pemmaraju, Nitin Jain, Rashmi Malla, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi and Hagop M. Kantarjian. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood 132, 2018.
Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Koji Sasaki, Naval G. Daver, Elias J. Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Caitlin R. Rausch, Yvonne Gasior and Hagop M. Kantarjian. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018.
Nitin Jain, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Gautam Borthakur, Prithviraj Bose, Zeev E. Estrov, Tapan M. Kadia, Koichi Takahashi, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur Patel, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M. Kantarjian, Susan M. O'Brien, Michael J Keating and William G. Wierda. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 132, 2018.
Naveen Pemmaraju, Bing Z Carter, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia, Guillermo Garcia-Manero, Courtney D. DiNardo, Prithviraj Bose, Naval G. Daver, Marina Y. Konopleva, Maro N. Ohanian, Sherry A. Pierce, Lingsha Zhou, Zeev E. Estrov, Gautam Borthakur, Karina Salinas, Po Yee Mak, Nitin Jain, Elias J. Jabbour and Srdan Verstovsek. LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood 132, 2018.
Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Kristy R. Bodden, Prithviraj Bose, Yesid Alvarado, Naval G. Daver, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Jorge E. Cortes, Elias J. Jabbour, Kiran Naqvi, Courtney D. DiNardo, Christopher B. Benton, Naveen Pemmaraju, Tapan M. Kadia, Maro N. Ohanian, Sherry A. Pierce and Hagop M. Kantarjian. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 132, 2018.
Nitin Jain, Michael J Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Nathan H. Fowler, Tapan M. Kadia, Marina Y. Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro N. Ohanian, Naveen Pemmaraju, Elias J. Jabbour, Koji Sasaki, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Naveen Garg, Xuemei Wang, Katrina Sondermann, Nichole Cruz, Chongjuan Wei, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi and William G. Wierda. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood 132, 2018.
Nicholas J Short, Hagop M. Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M. Kadia, Naval G. Daver, Maro N. Ohanian, Courtney D. DiNardo, Zeev E. Estrov, Rashmi Kanagal-Shamanna, Abhishek Maiti, Christopher B. Benton, Prithviraj Bose, Yesid Alvarado, Elias J. Jabbour, Steven M. Kornblau, Naveen Pemmaraju, Nitin Jain, Yvonne Gasior, Mary Ann Richie, Sherry A. Pierce, Jorge E. Cortes, Marina Y. Konopleva, Guillermo Garcia-Manero and Farhad Ravandi. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 132, 2018.
Dyana T. Saenz, Warren Fiskus, Taghi Manshouri, David N Saenz, Raffaella Soldi, Baohua Sun, Christopher Peter Mill, Agnieszka J Nowak, Steven M. Kornblau, Prithviraj Bose, Tapan M. Kadia, Courtney D. DiNardo, Lucia Masarova, Steve Horrigan, Joseph David Khoury, Sunil Sharma, Srdan Verstovsek and Kapil N. Bhalla. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis. Blood 132, 2018.
Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Naval G. Daver, Elias J. Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Simona Colla, Hui Yang, Caitlin R. Rausch, Yvonne Gasior, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Keyur P. Patel and Hagop M. Kantarjian. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018.
Prajwal Boddu, Gautam Borthakur, Kiran Naqvi, William G. Wierda, Prithviraj Bose, Elias Jabbour, Zeev Estrov, Jan Andreas Burger, Yesid Alvarado, APRIL Deshmukh, Ami Patel, Antonio Cavazos, Lina Han, Hagop M. Kantarjian, Michael Andreeff, Marina Konopleva. Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Gabriela Sanchez-Petitto, Guillermo Garcia-Manero, Nicholas James Short, Kiran Naqvi, Michael Andreeff, Koichi Takahashi, Steven Kornblau, Prithviraj Bose, Zeev Estrov, Marina Konopleva, Ami Patel, Rabiul Islam, Yesid Alvarado, Courtney Denton Dinardo, Hagop M. Kantarjian, Elias Jabbour. Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Boyu Hu, Keyur Patel, Hsiang-Chun Chen, Xuemei Wang, Rajyalakshmi Luthra, Mark Routbort, Rashmi Kanagal-Shamanna, L Jeffrey Medeiros, Cameron C. Yin, Zhuang Zuo, Chi Ok, Sanam Loghavi, Philip A. Thompson, Michael J. Keating, Jan Andreas Burger, Nitin Jain, Alessandra Ferrajoli, Prithviraj Bose, Zeev Estrov, William G. Wierda. Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL). J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Ahmad Ghorab, Hagop M. Kantarjian, Preetesh Jain, Rashmi Kanagal-Shamanna, Elias Jabbour, Koji Sasaki, Tapan M. Kadia, Guillermo Garcia-Manero, Prithviraj Bose, Musa Yilmaz, Kiran Naqvi, William G. Wierda, Srdan Verstovsek, Nitin Jain, Zeev Estrov, Farhad Ravandi, Susan Mary O'Brien, Jorge E. Cortes.. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Lucia Masarova, Srdan Verstovsek, Jorge Cortes, Naveen Pemmaraju, Elias Jabbour, Prithviraj Bose, Maro Ohanian, Lingsha Zhou, Sherry Pierce, Romany Gergis, Gautam Borthakur, Zeev Estrov, Guillermo Garcia-Manero, Hagop Kantarjian, Naval Daver.. PHASE 2 STUDY OF RUXOLITINIB IN COMBINATION WITH 5-AZACITIDINE IN PATIENTS WITH MYELOFIBROSIS. Hemasphere 2(suppl 1), 2018. e-Pub 2018.
Guillermo Garcia-Manero, Prithviraj Bose, Yesid Alvarado, Gautam Borthakur, Naval Daver, Farhad Ravandi-Kashani, Elias Jabbour, Koichi Takahashi, Michael Andreeff, Tapan Kadia, Courtney DiNardo, Jorge Cortes, Steven Kornblau, Kiran Naqvi, Christopher Benton, Maro Ohanian, Marina Konopleva, Zeev Estrov, Guillermo Montalban-Bravo, Sherry Pierce, Kristy Bodden, Hagop Kantarjian.. A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME. Hemasphere 2(suppl 1), 2018. e-Pub 2018.
Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda W. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood, 2017.
Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2017.
Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. Blood 130, 2017.
Yilmaz M, Kantarjian HM, Wang X, KC D, Khoury JD, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda W, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130, 2017.
Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, Konopleva M, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, O'Brien SM, Jabbour EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood 130, 2017.
Hu B, Patel K, Wang X, Chen H-C, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Wierda WG. Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots. Blood 130, 2017.
Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood 130, 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Takahashi K, Garg N, Wang X, Gandhi V, Plunkett W, Kanagal-Shamanna R, Patel K, Lopez W, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 130, 2017.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes J, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130, 2017.
Ghorab A, Jain P, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood 130, 2017.
Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N, Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U, Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood 130, 2017.
Bose P, Pemmaraju N, Schroeder K, Ferrajoli A, Jabbour EJ, Daver N, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood 130, 2017.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Pemmaraju N, KC D, Pierce S, Patel KP, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes JE, Kantarjian HM, Andreeff M, Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. Blood 130, 2017.
Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. Blood 130, 2017.
Bose P, Daver N, Pemmaraju N, Jabbour EJ, Estrov Z, Pike A, Huynh-Lu J, Nguyen-Cao M, Wang X, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia. Blood 130, 2017.
Srour S, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 130, 2017.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells. Blood 130, 2017.
Bose P, Chen L, Cruz N, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll M, Jain N, Wierda WG, Keating MJ, Gandhi V. A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia (CLL). Blood 130, 2017.
Naqvi K, Cortes JE, Skinner J, Jabbour EJ, Pemmaraju N, Bose P, Thompson PA, Borthakur G, Estrov Z, Kantarjian HM. Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Blood 130, 2017.
Boddu P, Mansurov A, Masarova L, Bose P, Patel KP, Estrov Z, Kantarjian HM, Verstovsek S. Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood 130, 2017.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. Blood 130, 2017.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib. Blood 130, 2017.
Falchi L, Chihara D, Bose P, Estrov Z, Kantarjian HM, Ravandi F, Verstovsek S. Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes. Blood 130, 2017.
Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. JAK2 V617F Acute Lymphoblastic Leukemia Secondary to Myeloproliferative Neoplasms (MPNs) or After Lenalidomide Exposure: Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S254, 2017.
Naqvi K, Cortes J, Skinner J, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson P, Kantarjian H. Therapy with Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Clin Lymphoma Myeloma Leuk 17(Suppl 2):S317, 2017.
Masarova L, Bose P, Abou Zahr A, Cortes J, Kantarjian H, Verstovsek S. Do We Need to Re-Define Accelerated Phase of Myelofibrosis? Correlation between Blast Percentage in Myelofibrosis and Outcomes. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S352, 2017.
Masarova L, Bose P, Newberry K, Abou Zahr A, Cortes JE, Kantarjian HM, Verstovsek S.. Correlation between blast percentage in myelofibrosis and outcomes: a single-center experience. J Clin Oncol 35, 2017.
Bose P, Nazha A, Komrokji R, Savona M, Patel K, Pierce S, Al Ali N, Sochacki A, Shaver A, Daver N, DiNardo C, Garcia-Manero G, Bueso-Ramos C, Kantarjian H, Sekeres M, Maciejewski J, Verstovsek S. MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM -. Haematologica (Roma) 102:118, 2017.
Naqvi K, Kadia T, Borthakur G, Takahashi K, Bose P, Daver N, Alvarado Y, Ohanian M, DiNardo C, Jabbour E, Garcia-Manero G, Kantarjian H, Patel A, Ravandi F. PHASE I/II STUDY OF MEK INHIBITOR (MEK-162; BINIMETINIB) IN PATIENTS WITH RELAPSED AND/OR. Haematologica (Roma) 102:375, 2017.
Garcia-Manero G, Daver N, Montalban-Bravo G, Jabbour E, DiNardo C, Kornblau S, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes J, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez G, Bueso-Ramos C, Gasior Y, Bayer V, Pierce S, Yang H, Colla S, Kantarjian H. AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS). Haematologica (Roma) 102:183, 2017.
Bose P, Daver N, Jabbour EJ, Pike A, Newberry KJ, Zhou L, Pierce S, Wang X, Kantarjian HM, Verstovsek S. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood 128, 2016. e-Pub 2016.
Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Brandt M, Pierce S, Nogueras-Gonzalez GM, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood 128, 2016. e-Pub 2016.
Benton CB, Takahashi K, Bose P, Wang F, Chen H-C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa G, Daver N, Jabbour E, DiNardo C, Bueso-Ramos C, Patel K, Kornblau S, Konopleva M, Borthakur G, Kadia T, Cortes J, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian H. Archetypes of AML defined using whole exome sequencing and clinical characteristics in a diverse group of patients. Blood 128, 2016. e-Pub 2016.
Masarova L, Popat U, Bose P Champlin R, Cortes J, Kantarjian H, Verstovsek S. Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy. Blood 128, 2016. e-Pub 2016.
Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes J, DiNardo C, Jabbour E, Kadia T, Kornblau S, Ohanian M, Alfonso A, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Initial results of a Phase 2 Study of Guadecitabine (SGI-110), A Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128, 2016. e-Pub 2016.
Jain P, Wang S, Kantarjian H, Sarwari N, Patel KP, Bose P, Pierce S, Kadia TM, Daver N, Pemmaraju N, Cortes J, Verstovsek S. Aleukemic mast cell leukemia (aMCL) – clinical characteristics and outcomes. Blood 128, 2016. e-Pub 2016.
Abaza Y, Kantarjian H, Jabbour E, Thomas D, Kadia T, Borthakur G, Burger J, Wierda W, Jain N, Faderl S, O'Brien S, Konopleva M, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Bose P, Thompson P, Kelly M, Garris R, Garcia-Manero G, Cortes J, Ravandi F. Phase II Study of Hyper-CVAD plus Nelarabine in Previously Untreated Adult T-cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) as Therapy for Patients (pts) with Myelofibrosis (MF). Blood 128, 2016. e-Pub 2016.
Khan M, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo C, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour E, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine as Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood 128, 2016. e-Pub 2016.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 128, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Daver N, Kadia T, Khouri RB, Alvarado Y, Burger J, Thomas D, Garcia-Manero G, DiNardo C, Pemmaraju N, Garris R, Schroeder H, Bose P, Jain N, Naqvi K, Wierda W, Verstovsek S, Cortes J, Konopleva M, O'Brien S, Jabbour E. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128, 2016. e-Pub 2016.
Pemmaraju N, Carter BZ, Kantarjian H, Cortes J, Kadia T, Garcia-Manero G, DiNardo C, Bose P, Pierce S, Zhou L, Estrov Z, Tuttle C, Salinas K, Mak PY, Verstovsek S. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood 128, 2016. e-Pub 2016.
Sasaki K, Jabbour E, O'Brien S, Thomas D, Ravandi F, Garcia-Manero G, Cortes J, Short N, Verstovsek S, Yilmaz M, Wierda W, Borthakur G, Kadia T, Konopleva M, Khouri M, Ferrajoli A, Daver N, Pemmaraju N, DiNardo C, Jain N, Benton C, Takahashi K, Naqvi K, Bose P, Kornblau S, Andreeff M, Keating M, Freireich E, Kantarjian H. Outcome of Patients with Acute Lymphoblastic Leukemia (ALL) by Age Group over 35 Years: A Single Institution Experience. Blood 128, 2016. e-Pub 2016.
Short NJ, Jabbour E, Sasaki K, Ko H, Ravandi F, Yin C, Khouri MR, Cortes JE, Garris R, O'Brien SM, Patel K, Garcia-Manero G, Thomas D, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian H. Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood 128, 2016. e-Pub 2016.
Ohanian M, Kantarjian H, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt J, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-dose Ara-C in Multiply Relapsed/ Refractory FLT3+ AML. Blood 128, 2016. e-Pub 2016.
Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128, 2016. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda WG, Keating M, Estrov Z. Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo. Blood 128, 2016. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda W, Keating M, Estrov Z. Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells. Blood 128, 2016. e-Pub 2016.
Strati P, Bose P, Gaw K, Zhou L, Pierce S, Huynh-Lu J, Bueso-Ramos CE, Verstovsek S. Immature Platelet Fraction Is Associated with JAK2 V617F Mutation and Features of Advanced Disease in Myelofibrosis. Blood 128, 2016. e-Pub 2016.
Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Daver NG, Bose P, DiNardo CD, Pemmaraju N, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood 128, 2016. e-Pub 2016.
Masarova L, Bose P, Daver N, Newberry KJ, Cortes JE, Garcia-Manero G, Kantarjian HM, Verstovsek S. Clinical characteristics of patients with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis and deletion 13q. Clin Lymphoma Myeloma Leuk 16(S2), 2016.
Masarova L, Bose P, Newberry KJ, Cortes JE, Garcia-Manero G, Kantarjian HM, Verstovsek S. Therapy-Related Myelofibrosis does not appear to exist. Clin Lymphoma Myeloma Leuk 16(S2), 2016.
Masarova L, Bose P, Pemmaraju N, Daver NG, Newberry K, Cortes JE, Kantarjian HM, Verstovsek S. Does therapy-related myelofibrosis exist? Analysis of 1100 myelofibrosis cases from a single institution. J Clin Oncol 34, 2016.
Alhuraiji A, Masarova L, Bose P, Daver NG, Cortes JE, Pierce S, Kantarjian HM, Verstovsek S. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. J Clin Oncol 34, 2016.
Lucia Masarova, MD, Prithviraj Bose, MD, Naveen pemmaraju, MD, Kate J Newberry, PhD, Carlos E Bueso-Ramos, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD. Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis. Blood 128(22):4265, 2016.
Koji Sasaki, Elias J. Jabbour, Susan M. O'Brien, Deborah A Thomas, Farhad Ravandi, Guillermo Garcia-Manero, Jorge E. Cortes, Nicholas J. Short, Srdan Verstovsek, Musa Yilmaz, William G. Wierda, Gautam Borthakur, Tapan M.Kadia, Marina Konopleva, Maria R. Khouri, Alessandra Ferrajoli, Naval G. Daver, Naveen Pemmaraju, Courtney DDiNardo, Nitin Jain, Christopher B. Benton, Koichi Takahashi, Kiran Naqvi, Prithviraj Bose, Steven M. Kornblau, Michael Andreeff, Michael J. Keating, Emil J. Freireich, Hagop M. Kantarjian. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22):3975, 2016.
Yilmaz M, Kantarjian HM, Cortes J, Garcia-Manero G, Chahoud J, Ravandi F, Sasaki K, Takahashi K, Wierda WG, Jain N, Verstovsek S, Estrov Z, Bose P Pierce S, Jabbour E.. Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood 126(23), 2015.
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM.. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23), 2015.
Jain PL, Sasaki K, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Bravo Montalban G, Pierce S, Jabbour E.. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood 126(23), 2015.
KC B, Kantarjian HM, Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes JE.. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood 126(23), 2015.
Masarova L, Daver N, Pemmaraju N, Bose P, Pierce S, Manshouri T, Cortes JE, Kantarjian HM, Verstovsek S.. Do Patients with Post-Essential Thrombocythemia and post-Polycthemia Vera Differ from Patients with Primary Myelofibrosis?. Blood 126(23), 2015.
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Shuo Ma, Amy Kimball, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, April Dean, Sarah Conine, Heidi Sankala, John D. Roberts, Thomas C. Shea & Steven Grant.. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results. Blood 124(21), 2014.
Joshua F. Zeidner, Matthew C. Foster, Amanda Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, Yair Levy, Raoul Tibes, Ivana Gojo, Chistopher D. Gocke, Jacqueline M. Greer, Joan M. Cain, Richard F. Little, John J. Wright, L. Austin Doyle, B. Douglas Smith & Judith E. Karp.. Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 32, 2014.
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Paul M. Barr, Mary Beth Tombes, Ellen Shrader, Erin Cebula, Emily Pierce, Megan M. Herr, Heidi Sankala, Changyong Feng, Richard I. Fisher, Steven Grant, Jonathan W. Friedberg.. Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. Blood 122, 2013.
Joshua F. Zeidner, Jonathan M. Gerber, Amanda Blackford, Mark Litzow, Matthew Foster, Lawrence Morris, Ivana Gojo, Jeffrey Lancet, Prithviraj Bose, Raoul Tibes, Stephen Strickland, Jacqueline Greer, Michelle Drye, Kevin Meads, L. Austin Doyle, Richard F. Little, John J. Wright & Judith E Karp.. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 120(21), 2012.
Beata Holkova, Thomas C. Shea, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Steven Grant.. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood 120(21), 2012.
Beata Holkova, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Guillermo Garcia-Manero, Steven Grant.. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis – One Year Update. Blood 120(21), 2012.
Beata Holkova, E. Brent Perkins, Prithviraj Bose, Daniel Sullivan, Rachid C. Baz, Mary Beth Tombes, Ellen Shrader, Viswanathan Ramakrishnan, Wen Wan, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Steven Grant.. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms – Update of the “Bolus” Infusion Schedule of Alvocidib. Blood 120(21), 2012.
Li J, Gatesman ML, Newland AM, Sabo R, Bose P.. FLAG ± Idarubicin Compared with 7+3 As Initial Induction for Secondary Acute Myeloid Leukemia: A Single Institution Experience. Blood 120(21), 2012.
Bose P, Holter JL, Selby GB.. Use of Bevacizumab in Hereditary Hemorrhagic Telangiectasia. Blood 112(11):1338, 2008.
Bose P, Nakadar S, Ali AY, Reyes MP.. Daptomycin-induced rhabdomyolysis. J Gen Int Med 22(S1):240, 2007.
Bose P, Al-Romaihi D, Movva K.. Hypokalemic periodic paralysis: Not always familial. J Gen Int Med 22(S1):211, 2007.
Bose P, Shah V.. Clinically confirmed Heparin Induced Thrombocytopenia (HIT) presenting with Unusually Low Platelet Count and Negative HIT Antibodies. J Gen Int Med 21(S4):231, 2006.
Bose P, Thompson JA.. Fatal HHV-6 Encephalitis following treatment of High Grade T Cell Non Hodgkin Lymphoma with Autologous Stem Cell Transplantation and Campath. J Gen Int Med 21(S4):237, 2006.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry K, Cortes J, Kantarjian H, Verstovsek S. Cytogenetic risk stratification in primary versus post-essential thrombocythemia / post-polycythemia vera myelofibrosis. Blood 128. e-Pub 2016.
Masarova L, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG.. Phase 2 study of Ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. J Clin Oncol 35. e-Pub 2017.
Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau S, Ohanian M, Huang X, Nogueras-Gonzalez GM, Bodden K, Pierce S, Kantarjian HM, Garcia-Manero G.. Updated results from Phase 2 Study of Guadecitabine for Patients with Higher Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia. J Clin Oncol 35. e-Pub 2017.
Assi R, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Kadia TM, DiNardo CD, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG.. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). J Clin Oncol 35. e-Pub 2017.
Boddu P, Jorgensen JL, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour E, Garcia-Manero G, Cortes JE, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces risk of relapse. J Clin Oncol 35. e-Pub 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Gandhi V, Plunkett W, Lopez W, Kantarjian HM, O’Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV and Non-del(17p). J Clin Oncol 35. e-Pub 2017.
Naqvi K, Cortes JE, Skinner JA, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson PA, Kantarjian HM.. Early Results of Lower Dose Dasatinib, 50mg Daily, in Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase. J Clin Oncol 35. e-Pub 2017.

Book Chapters

Bose P, Masarova L, Amin H, Verstovsek S. Philadelphia Chromosome Negative Myeloproliferative Neoplasms. In: MD Anderson Manual of Medical Oncology. 4. McGraw Hill: New York, 2022.
Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice, 2020.
Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice. BMJ Publishing Group Limited: United Kingdom, 2018.
Bose P, Verstovsek S. Polycythemia vera. In: BMJ Best Practice, 2016.
Bose P, Grant S.. Bcl-2 family: translational aspects. In: Targeted Therapy of Acute Myeloid Leukemia. Springer: New York, 67-94, 2015.
Dai Y, Bose P, Grant S.. Cell cycle regulation and hematologic disorders. In: Williams Hematology. 9. Mc-Graw Hill: New York, 2015.
Bose P, Vachhani P.. Can we cure CML without transplantation?. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova: New York, 279-326, 2014.
Ustun C, Warlick E, Bose P, Radich JP, Goldman JM.. Summary of treatment and recommended follow-up of CML patients. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova: New York, 183-190, 2014.
Batalo MS, Bose P, Holkova B, Grant S.. Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition. In: Resistance to Proteasome Inhibitors in Cancer. Springer: Switzerland, 149-179, 2014.
Poklepovic A, Bose P. Molecularly Targeted Therapy: Imatinib and Beyond. In: Gastrointestinal Stromal Tumor. InTech: Croatia, 47-60, 2012.
Park H, Poklepovic A, Bose P.. Emerging therapeutic options for metastatic exocrine pancreatic cancer. In: Pancreas: Anatomy, Diseases and Health Implications. Nova: New York, 159-172, 2012.
Bose P, Verstovsek S. Polycythemia vera. In: Cancer Consult: Uncertainties and Controversies in the Diagnosis & Management of Cancer. 2nd. Wiley-Blackwell Health Sciences, John Wiley and Sons.

Letters to the Editor

Bose P, Holter JL, Selby GB.. More on Bevacizumab in Hereditary Hemorrhagic Telangiectasia (author reply). N Engl J Med 361: 931-932, 2009.

Less

Grant & Contract Support

Title:	2015-0787_Alternating or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Funding Source:	Pfizer
Role:	Principal Investigator

Title:	2015-0832_A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Funding Source:	Blueprint Medicines Corporation
Role:	Principal Investigator

Title:	2016-0373_A Phase II study of isavuconazole prophylaxis in adult patients with AML/MDS and neutropenia
Funding Source:	Astellas Pharma
Role:	Principal Investigator

Title:	2017-0111_A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea
Funding Source:	Incyte Corporation
Role:	Principal Investigator

Title:	2017-0320_An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Funding Source:	CTI BioPharma
Role:	Principal Investigator

Title:	2017-0512_EVALUATION OF RUXOLITINIB and THALIDOMIDE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS
Funding Source:	Memorial Sloan Kettering Cancer Center
Role:	Principal Investigator

Title:	2017-0504_A phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept (ACE-536) in subjects with myeloproliferative neoplasm-associated myelofibrosis and anemia with and without red blood cell-transfusion dependence
Funding Source:	Celgene Corporation
Role:	Principal Investigator

Title:	2018-0022_An Open-Label, Multi-center, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Funding Source:	Incyte Corporation
Role:	Principal Investigator

Title:	2018-0202_A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Funding Source:	Constellation Pharmaceuticals, Inc
Role:	Principal Investigator

Title:	2018-0943_An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Funding Source:	Blueprint Medicines
Role:	Principal Investigator

Title:	2018-0906_An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
Funding Source:	Kartos Therapeutics
Role:	Principal Investigator

Title:	2018-0907_A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Funding Source:	Kartos Therapeutics
Role:	Principal Investigator

Title:	2013-0051_A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
Funding Source:	Promedior
Role:	Principal Investigator

Title:	2020-0522_"A pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis"
Funding Source:	Bristol-Myers Squibb
Role:	Principal Investigator

Title:	2021-0587 A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Funding Source:	Cogent Biosciences
Role:	Principal Investigator

Title:	2021-0880 (SUMMIT) A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY OF THE SAFETY AND EFFICACY OF CGT9486 IN SUBJECTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS CGT9486-21-202
Funding Source:	Cogent Biosciences
Role:	Principal Investigator

Title:	2021-0331 BLU-285-2203 - A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Funding Source:	Blueprint Medicine
Role:	Principal Investigator

Title:	2021-0897: A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
Funding Source:	Ionis Pharmaceuticals
Role:	Principal Investigator

Prithviraj Bose, M.D.

About Dr. Bose

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Prithviraj Bose, M.D.

About Dr. Bose

Primary Appointment

Degree-Granting Education

Postgraduate Training

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Give Now

Donate Blood

Volunteer